This record was last updated April 13, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single dose, randomized, open-label, two-way crossover study to investigate the food-effect bioavailability of the fixed-dose combination of Gemigliptin/Dapagliflozin/Metformin 50/10/1000 mg in healthy volunteers under fasting and fed conditions.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-02.